Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.
Zeig mir, was ich alles machen kann

CHF Solutions Inc Aktie

Die CHF Solutions Inc Aktie hat heute herbe Verluste von -5,67 % aufzuweisen.

Was spricht für und gegen CHF Solutions Inc in den nächsten Jahren?

Pro
1
Eventuell sehr lohnenswerte Investition > 20% pro Jahr
Kontra
0
-

Kommentare

Buy mit Kursziel 0,0

CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration

September 10, 2020 09:15 ET | Source: CHF Solutions, Inc.

EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment of fluid overload in heart failure (HF) patients, including alternatives to diuretics, such as ultrafiltration using the Aquadex SmartFlow™ system.

Clinically important observations made by Dr. Jefferies during the webinar include:

  • The impact of fluid overload on HF patients is significant. 90% of HF hospitalizations are due to signs and symptoms of fluid overload.1
  • Common fluid overload treatment approaches such as diuretics are associated with mixed outcomes and adverse events. Studies have shown 42% of acutely decompensated HF patients either return to the emergency room, are re-hospitalized or die within 60 days of hospital discharge, regardless of diuretic strategy.2
  • Ultrafiltration is an effective treatment strategy for patients with HF.  When compared to diuretics, there is a 53% reduction in the risk of rehospitalization among HF patients receiving ultrafiltration.3
  • The use of ultrafiltration after cardiac surgery has been shown to improve cardiac performance, 4 reduce the duration of assisted ventilation5 and can reduce the need for blood transfusions.6
“Ultrafiltration has continued to demonstrate efficacy in various clinical settings, and heart failure is a significant area where Aquadex™ has proven to be advantageous in the delivery of effective patient care,” said John Erb, CEO of CHF Solutions. “Dr. Jefferies’ experience provides valuable insights for heart failure clinicians and beyond. There are many patients who can benefit from ultrafiltration therapy and this educational webinar helps to ensure providers are equipped with knowledge of various treatment options for fluid overloaded patients.”

Dr. Jefferies also discussed Aquadex-specific considerations and recommendations in regard to venous access, anticoagulation, ultrafiltration rate and Hematocrit (HCT) and SV02 monitoring.  Access this information and a white paper analysis by watching the webinar replay available on the company website and on CHF Solutions’ YouTube page.  Dr. Jefferies’ presentation will be a part of the company’s offerings at the 24th Annual Scientific Meeting of the Heart Failure Society October 3-5, 2020.

Dr. Jefferies serves as Director of the Methodist University of Tennessee Cardiovascular Institute. He is a Professor of Pediatric Cardiology, Professor of Preventive Medicine, and a Research Member of St. Jude Children’s Research Hospital. Dr. Jefferies has published 200 peer-reviewed manuscripts and is the Lead Editor for two widely acclaimed textbooks.

Quelle: GlobeNewswire

Geschrieben 23.08.20
Einschätzung Buy
Rendite (%) -
Kursziel 1,00
Veränderung

Buy mit Kursziel 1,0

Mehr anzeigen
Du kannst diesen Artikel nicht kommentieren, da du deinen Account noch nicht bestätigt hast oder geblockt wurdest. Sollte du das für einen Fehler halten, kontaktiere uns bitte. Mehr anzeigen

Weitere Diskussionen zu CHF Solutions Inc Aktie

Trading CHF Solutions Inc

Trading CHF Solutions Inc

Neue Diskussion in Forum